@tinks wrote:
@god wrote:
Shionogi-ViiV Healthcare, LLC announced today that the first patient has entered the clinical study, SINGLE (ING114467), designed to support a new fixed-dose combination (FDC) therapy for the treatment of HIV. The new investigational regimen, known as 572-Trii, will combine the investigational integrase inhibitor, S/GSK1349572 (‘572), and ViiV Healthcare’s combination nucleoside reverse transcriptase inhibitor (NRTI) Kivexa®/Epzicom® (ABC/3TC).
any chance of a brief explanation? :lol:
the u- 573 was a german u-boat of world war two…….unlike many other u- boats which during their service lost men due to accidents and various other causes u – 573 did not suffer any casualties (that are known about) until the time of her loss.
No problem tinks me old mucka :D
you see, it’s all to do with the investigational integrase inhibitor being combined with the nucleoside reverse transcriptase
is that brief enough for you? :lol:
The New Balance 574 running shoe combines the look that made us famous with the technologies that made us a favorite.